27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Axonics Inc (NASDAQ:AXNX) reported a Q1 EPS loss of $(0.19), better than the consensus of $(0.29). Sales increased 46% Y/Y to $70.65 million, beating the consensus of $65.26 million.
The company expects FY23 sales of $348 million, compared to earlier guidance of $342 million versus the consensus of $343.77 million.
Piper Sandler says the guidance could ultimately prove conservative again.
AXNX also shows favorable operating leverage down the P&L, and the recently completed tuck-in M&A transaction for a lead placement technology offers an intriguing future complement to the sacral neuromodulation business.
It reiterates the Overweight rating with a price target of $84.
Needham writes that given AXNX's 46% growth in 1Q23, 27% revenue growth guidance is conservative.
The analyst notes that Axonics' F15 non-rechargeable SNM system, launched in April 2022, offers nearly twice the battery life of Medtronic Plc's (NYSE: MDT) InterStim X non-rechargeable system, along with other advantages.
The F15 is enabling AXNX to capture market share from Medtronic.
It reiterates the Buy rating with a price target of $73 from $71 due to a higher revenue estimate.
Price Action: AXNX shares are down 10.40% at $52.57 on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!